Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae

• Príomhchruthaitheoirí: Hong Luo (Údar), Yanping Xiao (Údar), Yaping Hang (Údar), Yanhui Chen (Údar), Hongying Zhu (Údar), Xueyao Fang (Údar), Xingwei Cao (Údar), Shan Zou (Údar), Xiaoyan Hu (Údar), Jianqiu Xiong (Údar), Qiaoshi Zhong (Údar), Longhua Hu (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: BMC, 2021-09-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Abstract Background Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae has become a public health concern. This study aimed to compare the clinical outcomes of patients with nonurinary source bacteraemia caused by ESBL-producing Escherichia coli (E. coli) or Klebsiella pneumoniae (ESB...